Epitalon Compounding Legal Status: What Patients and Providers Need to Know
A detailed look at Epitalon's FDA regulatory status, compounding legality, safety data, and what the absence of an approved label means for prescribers and patients.
Epitalon: Regulatory History
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
8articles
3topic areas covered
Jan 28, 2025latest review
Epitalon: Regulatory History library
Showing 8 of 8 clinical reviews.
Epitalon EMA vs FDA Approach: Regulatory Status, Safety, and What Patients Need to Know
A detailed comparison of how the FDA and EMA view epitalon tetrapeptide, covering approval status, labeling, safety data, and what that means for clinical use in 2024.
Epitalon FAERS Safety Signals: What the FDA Adverse Event Data Actually Shows
A clinician-focused review of Epitalon FAERS safety signals, FDA regulatory status, absence of approved labeling, and what post-market surveillance data does and does not tell us about this unscheduled tetrapeptide.
Epitalon FDA Approval History
Epitalon (epithalon tetrapeptide, Ala-Glu-Asp-Gly) has never received FDA approval. This article covers its regulatory status, the Russian clinical literature behind it, and what patients should know before considering this research peptide.
Epitalon Global Regulatory Status: FDA, EMA, and International Classification
Epitalon (Ala-Glu-Asp-Gly) has no FDA or EMA approval. Learn the current regulatory classification in the US, EU, Russia, Australia, and other markets, plus what the science actually shows.
Epitalon Label Updates 2020 to 2026: FDA Status, Safety Data, and Regulatory Timeline
A full regulatory and clinical review of epitalon tetrapeptide covering FDA status, no approved label, compounding restrictions, and published safety data from 2003 to 2026.
Epitalon Legal and Patent Challenges: FDA Status, Regulatory Barriers, and What Clinicians Should Know
Epitalon (epithalon) has no FDA approval, no active U.S. patent protection, and no completed phase III trials. This article covers the peptide's regulatory status, legal gray areas, and what the clinical evidence actually supports.
Epitalon Pipeline and Next-Gen Research: FDA Status, Safety Data, and What Comes After the Tetrapeptide
Epitalon has no FDA approval and remains a research-only peptide. This article covers its regulatory status, published safety signals, clinical trial gaps, and the next-generation telomerase-targeting compounds in early development.